Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more
Samsung Biologics Co Ltd (207940) - Total Liabilities
Latest total liabilities as of September 2025: ₩6.16 Trillion KRW
Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has total liabilities worth ₩6.16 Trillion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Samsung Biologics Co Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Samsung Biologics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Samsung Biologics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Samsung Biologics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alstom S.A.
PA:ALO
|
France | €24.68 Billion |
|
Cullen/Frost Bankers Inc
NYSE:CFR
|
USA | $48.07 Billion |
|
Shandong Hualu Hengsheng Chemical Co Ltd
SHG:600426
|
China | CN¥14.58 Billion |
|
NWOEF
PINK:NWOEF
|
USA | $4.09 Billion |
|
UMB Financial Corporation
NASDAQ:UMBF
|
USA | $65.40 Billion |
|
Sanrio Company Ltd
PINK:SNROF
|
USA | $69.58 Billion |
|
National Fuel Gas Company
NYSE:NFG
|
USA | $5.62 Billion |
|
AltaGas Ltd
PINK:ATGFF
|
USA | $16.91 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Samsung Biologics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Samsung Biologics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Samsung Biologics Co Ltd (2014–2024)
The table below shows the annual total liabilities of Samsung Biologics Co Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩6.43 Trillion | +3.47% |
| 2023-12-31 | ₩6.22 Trillion | -18.19% |
| 2022-12-31 | ₩7.60 Trillion | +155.05% |
| 2021-12-31 | ₩2.98 Trillion | +63.19% |
| 2020-12-31 | ₩1.83 Trillion | +17.23% |
| 2019-12-31 | ₩1.56 Trillion | -14.67% |
| 2018-12-31 | ₩1.82 Trillion | -43.09% |
| 2017-12-31 | ₩3.21 Trillion | -7.07% |
| 2016-12-31 | ₩3.45 Trillion | +8.32% |
| 2015-12-31 | ₩3.19 Trillion | +339.42% |
| 2014-12-31 | ₩724.97 Billion | -- |